Skip to content
Polyphenol Extract / HMG-CoA Reductase Modulator

Citrus Bergamot

A polyphenol fraction from the Calabrian bergamot orange whose flavonoids — brutieridin and melitidin — carry a statin-like moiety that modulates HMG-CoA reductase. The best-supported natural option for lowering LDL and ApoB, with a meta-analysis behind it, as long as you read the effect sizes honestly: this is a fraction of statin potency, not a statin replacement.

cardiovascularmetabolic-healthlongevity
Tier AWell-tolerated — strong human evidence
Evidence gradeBControlled trials / Cohort studies
BH

Reviewed & fact-checked by

BiohackingHub Research Team

Editorial Research Team · Last updated: August 19, 2026

Verified

Why Bergamot Is Interesting

Most "cholesterol support" supplements are antioxidant stories with weak lipid data. Bergamot is different for one structural reason: two of its flavonoids, brutieridin and melitidin, carry a 3-hydroxy-3-methylglutaryl (HMG) moiety — the same chemical group that lets statins occupy HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis. Bergamot is, quite literally, the plant that makes a weak natural statin.

That gives it a mechanistic claim on LDL cholesterol and ApoB — the particle-count marker covered in ApoB and Lp(a): the markers that matter — rather than just triglycerides or "oxidation".

The Evidence

Meta-analysis (2022). A systematic review and meta-analysis of randomised trials found significant reductions in total cholesterol, LDL-C, and triglycerides with bergamot supplementation. Typical LDL reductions across trials cluster around 15–25% — meaningful, though trial quality varies and several trials share investigators with industry ties. Grade the evidence B, not A.

The sdLDL and subclinical atherosclerosis trial (2015). In subjects with moderate hypercholesterolaemia, bergamot polyphenol fraction reduced plasma lipids, shifted LDL subfractions away from small dense particles, and reduced carotid intima-media thickness over 6 months. The particle-subfraction shift is the most distinctive finding — it suggests the benefit is qualitative as well as quantitative.

Early human work (2011). The original Calabrian studies reported LDL reductions up to 30–40% at 1,000 mg/day of the polyphenol fraction. These numbers have not been consistently replicated at that magnitude — anchor expectations to the meta-analytic estimate, not the best-case trial.

What bergamot does not do: it does not meaningfully lower Lp(a) (nothing over-the-counter does), and it has never been tested against cardiovascular events. It is a biomarker intervention with a plausible mechanism — several steps short of outcome-proven.

Dosing and Standardisation

Trials used the bergamot polyphenol fraction (BPF) standardised to 38–40% polyphenols, mostly at 500–1,300 mg/day, taken before meals.

LabelWhat it means
"Bergamot extract 1000 mg"Meaningless without a polyphenol percentage
"38% polyphenols" / "BPF"The standard used in the positive trials
"Bergamonte / BPF 99"Branded forms matching the trial material

Practical target: 1,000 mg/day of a 38%+ standardised extract, retesting a lipid panel plus ApoB at 12 weeks.

Safety

Bergamot is one of the better-tolerated compounds in the cardiovascular space — trials up to 12 months report adverse events at placebo rates, with occasional heartburn the main complaint. Two flags worth knowing:

  • This is not grapefruit. The fruit-extract supplement has not shown the CYP3A4 interaction that makes grapefruit juice dangerous with statins, but formal interaction studies are sparse — coordinate with the prescriber if you take a narrow-index drug.
  • Statin combination is common and intentional — bergamot has been studied as an add-on allowing lower statin doses. That decision belongs to the prescribing physician, not the supplement aisle.

Related Research

Stacking Interactions

How Citrus Bergamot interacts with other compounds

+
Synergistic

The standard natural lipid pairing: bergamot works the synthesis pathway (HMG-CoA), berberine upregulates LDL-receptor expression and AMPK. Mechanisms complement rather than duplicate

+
Synergistic

Bergamot addresses LDL/ApoB, high-dose EPA addresses triglycerides and residual inflammatory risk — different lipid axes

+
Synergistic

No overlap: bergamot handles the lipid limb, nattokinase the fibrinolytic limb of cardiovascular risk

=
Neutral

Statin users adding bergamot often already take CoQ10; there is no evidence bergamot depletes CoQ10 the way full statin doses can

Protocols using Citrus Bergamot

Evidence-graded stacks that include this compound

Safety Profile — Tier A

Well-tolerated — strong human evidence

Contraindications

  • Known citrus allergy
  • Pregnancy and breastfeeding — insufficient data on concentrated extracts

Side Effects

  • Occasional heartburn or mild gastrointestinal discomfort
  • No serious adverse events reported in trials up to 12 months

Drug Interactions

Statins — additive LDL-lowering; combination is studied and generally intentional, but coordinate with the prescriberUnlike grapefruit, bergamot fruit extract has not shown clinically meaningful CYP3A4 inhibition at supplement doses, though data are limitedDiabetes medications — modest additive glucose-lowering possible